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Abstract 
Aims and Objectives 
To explore how community pharmacists use evidence to inform their practice 
when recommending or selling over-the-counter medicines. 
Methods 
Semi-structured face-to-face interviews were conducted during February 2013 
and analysed using the principles of content analysis.  
Results 
Sixteen pharmacists were interviewed. Pharmacists were aware of evidence 
based medicine and practice but relied on personal judgement augmented 
with patient feedback to make product recommendations. This was primarily 
due to the acknowledgement that many non-prescription medicines either had 
no or little evidence of efficacy. Pharmacists did and would use evidence to 
inform product selection if available but acknowledged that ineffective 
products were sold, especially when consumers asked for a named product. 
This was tempered by their attempts to inform the consumer of the products 
effectiveness, or lack of, or in the knowledge that it would cause them no 
harm.  
Conclusions 
Pharmacists took a pragmatic approach to product recommendation in light of 
the lack of clinical evidence to support their efficacy. 
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Introduction 
 
The global market for over-the-counter (referred to here in as non-
prescription) medicines is very considerable and rising with annual sales 
growth now outstripping that of prescription medicines [1]. For example, in 
2011, the UK market was worth £2.3 billion [2] and in the United States 
customers spent $17 billion in 2010 – a rise of over $3 billion over the 
preceding 10 years [3].  
 
A combination of factors has fuelled this world-wide increase in non-
prescription sales. These include government health care policies that 
encourage self-care and self-medication coupled with a greater emphasis on 
cost containment by health care organisations [4-5]. At the same time there 
has been an unprecedented rise in the number of medicines deregulated from 
prescription only control to non-prescription status [6-7].  
 
In the UK numerous health policy papers have been published detailing how 
maximising self-care can be achieved [8-12], with the contribution from 
community pharmacy being specifically highlighted [13-15]. Additionally, over 
80 medicines have now been switched from prescription to non-prescription 
status since the first occurred in 1983 [16]. Pharmacists can now sell or 
recommend a plethora of medicines ranging from traditional remedies that 
have been on the market for many years to recent prescription medicines, 
such as proton pump inhibitors or statins. These recent ‘switches’ are 
assessed on the basis of safety profile and efficacy, although efficacy is 
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usually drawn from data through prescription use rather than the intended 
non-prescription use.  
Over this period the practice of evidence-based medicine (EBM) has become 
firmly embedded in Western healthcare and is considered the gold standard 
by which all diagnostic and therapeutic interventions are judged. An evidence 
based approach can be defined as ‘the conscious, explicit and judicious use 
of current based evidence in making decisions about the care of individual 
patients’ [17]. EBM is now part of degree syllabus for pharmacists across the 
globe, and recognised by the World Health Organisation [18].  
 
Despite the upward sales trend for non-prescription medicines and 
governments’ continued promotion of self-care, to date little attention has 
been paid on how community pharmacists use evidence to inform practice 
when selling or recommending non-prescription medicines. Just one recent 
study by Hanna et al in Northern Ireland investigated what influenced non-
prescription product recommendations. They found that product safety rather 
than evidence was the most important factor considered by pharmacists [19]. 
This study’s aim was to explore how evidence was used (if at all) and to 
determine if safety, as shown by Hanna et al, was also the predominant factor 
in pharmacist choice.   
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Method 
 
Semi-structured face-to-face interviews were conducted with 16 pharmacists 
working from pharmacies in the West Midlands, England. Pharmacists 
belonging to the ‘Black Country’ local practice forum (covering the 
administrative and geographical areas of Dudley, Sandwell, Walsall and 
Wolverhampton) were sent information about the study. Those that expressed 
an interest in the study were then telephoned to arrange a suitable time and 
place for the interview to take place. This sampling strategy only yielded four 
participants. Subsequently convenience and snowball sampling was used to 
ensure sufficient participants to allow data saturation to be reached.	   
 
Prior to the interview, assurances were given over anonymity and 
confidentiality. Interviews were performed by EW at each pharmacist’s place 
of work. On the day of the interview participants were reminded of the 
purpose of the study and had the opportunity to ask questions before giving 
written consent. The interview schedule was developed by EW and drew on 
findings from work by Hanna [19].  
 
Questions were open-ended and explored how pharmacists used evidence of 
non-prescription products in patient consultations. The interview schedule was 
piloted on three pharmacists and showed that minor changes to wording were 
required to aid clarity and facilitated an interview of approximately 10 to 20 
minutes’ duration. Interviews took place in February 2013.  
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Interviews were audio recorded and transcribed verbatim. Nvivo software 
(QSR International Pty Ltd, UK) was used to manage the data and content 
analysis was used to identify any emergent themes; these were validated for 
context and understanding by a second member of the research team (PR).  
To assess participant validity, the first five transcripts were returned to 
participants to check that their individual opinions had been accurately 
represented. With regard to reflexivity, the interviewer (EW) had no 
relationship to any of the pharmacies or staff where interviews were 
conducted.  
 
Ethical approval was granted by The Behavioural Sciences Ethics 
Committee, University of Wolverhampton.  
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Results 
 
Sixteen community pharmacists participated in the study; nine were women 
and seven were men. The majority were employee pharmacists working for 
large national multiple chain pharmacies, although some were owners of their 
own pharmacy. It was clear that community pharmacists had a good 
understanding of the concept of EBM yet opportunities to exercise this 
approach when recommending non-prescription products was limited. All but 
one pharmacist stated that the lack of evidence associated with products was 
the primary reason: 
 
‘There is not much evidence out there. I know when I started I was like I am 
always going to give the best thing out there…It’s much easier with 
prescription medicines than it is with over-the-counter…over-the-counter, it’s 
all shiny boxes.’ (CP4) 
 
‘Most of the old products don’t have any evidence. No one proved that they 
are effective but they are still used. Some of the evidence of the new products 
is not very clear.’ (CP15) 
 
‘The evidence base of over-the-counter is sometimes questionable.’ (CP3) 
 
Because they were aware that many non-prescription products had either no 
or little evidence of efficacy they made decisions based on a combination of 
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factors that included, patient safety, risk minimisation, pharmacological action 
of medicine, placebo effect and personal experience/judgement: 
 
 ‘My first priority as a pharmacist is their (the patient) safety.’ (CP7)  
 
 
‘I use what I know from experience, feedback from patients, active 
ingredients, yeah that’s good enough.’ (CP12) 
 
‘As long as it’s not posing a risk to the patient I do not see the reason why we 
should not. I mean a lot of the products have no evidence so I see why people 
just recommend products using their own expertise.’ (CP13) 
 
‘I look at the active ingredients. I also usually recommend what I have used 
before so yeah pretty much personal experience’.  (CP6) 
 
‘I do have a number of patients that just walk in and want me to give them 
medications for conditions that do not need any treatment. It’s a psychological 
thing to be honest. They buy it in the belief that it works and it works for them, 
the placebo effect cannot be underestimated.’ (CP10) 
 
Personal experience/judgement appeared to have the greatest influence on 
decision making and was reinforced by patient/customer feedback, 
exemplified by the following comments:  
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‘Your experience will help you judge what actually works and what doesn’t. I 
also get to ask my patients on whether the products worked and this also 
helps.’ (CP15) 
 
‘There is not that much information out there anywhere and the little that is 
published is not that clear as well.  I am left with no choice but to use my 
personal judgment based on patients’ experiences and other factors to come 
up with decisions.’ (CP15) 
 
Pharmacists did acknowledge that they sold products to people where 
evidence was lacking, especially if patients/customers insisted on a particular 
product. However, all stated they would try to explain to the person the lack of 
evidence of the requested product(s). 
 
‘When parents ask for something for a cough for their child, I tell them that it 
will go away on its own and tell them to give the child plenty of fluids and 
rest…but if you want it and think that it will help soothe the throat then you can 
take it. It will not make the cough any better because there is no evidence to 
show that its effective.’ (CP3) 
 
‘There are a number of times I have said to people…yeah you are welcome to 
buy that because it does not do you any harm but I generally don’t think it will 
do you good either. I wouldn’t waste your money.’ (CP4) 
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The need to explain to the person seemed rooted in their professional values: 
 
The public puts so much trust in us. By recommending some product when 
you know it does not work is just like grabbing money out of their wallets. It’s 
just not right.’ (CP16) 
 
 ‘If someone has got a blood shot eye because they have sub-conjunctival 
haemorrhage that will get better by itself, I would not give them anything. I 
won’t just sell them ….Drug XXX when I know it’s not going to work.’ (CP6) 
 
‘It’s not professional to sell things like cough and cold remedies without even 
bothering to inform the patient that they don’t do any good.’ (CP8) 
 
Pharmacists were prepared to alter their practice if new or credible evidence 
became available: 
 
‘I don’t mind changing my practice to suit new evidence. If it turns out 
something is not as effective as I thought and a proven product comes out, I 
definitely use that.’ (CP12) 
 
‘I don’t have a problem with changing my practice to suite evidence because 
evidence changes all the time.’ (CP4) 
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Pharmacists spoke about being put under pressure to sell products to patients 
and commented on direct to consumer advertising being influential in shaping 
patient product choice. 
 
‘The fact that companies heavily advertise some products, patients just turn 
up with specific product requests not symptoms and no matter what you say 
they will not change their minds.’ (CP9) 
 
Even if you try and convince them to buy a more effective product they will 
just end up buying what they came in to buy in the first place. I blame most of 
this on adverts.  (CP13) 
 
Commercial pressure also had an influence on pharmacists, with both owners 
of pharmacies and employees of multiple chains speaking of financial 
pressures impacting on what products were supplied. 
 
‘We are sometimes told to try and push sales of certain products because the 
company gets them cheap from manufacturers.’ (CP2)  
 
‘Recommending an ineffective product is not ethical and not professional. 
Selling products, on the other hand is different. Some patients will insist on 
buying the product. Like I said, it’s a business for me, this is what pays my 
bills and I am not going to refuse to sell because no study was done on the 
product to prove its’ efficacy.’ (CP11) 
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Discussion 
 
Evidence of efficacy was not the key determinant for selection of non-
prescription products by community pharmacists in this study. This was 
primarily as a result of the lack of evidence associated with non-prescription 
products. Pharmacists were mindful that old products that pre-dated the 
requirement for licensure had no empirical evidence to substantiate claims 
and even those products recently switched from prescription control to non-
prescription use, at times, the evidence was questionable. This stance is 
grounded in fact [16].    
 
Pharmacists therefore tended to make decisions based on personal 
experience that was shaped by patient feedback in addition to the products 
ability to cause no harm. This latter finding is consistent with the findings of 
Hanna et al, although appeared to be less influential in the community 
pharmacist’s decision to supply products [19]. Pharmacists also spoke of 
utilising theoretical pharmacological action of medicines to substantiate a 
product recommendation and recognised the placebo effect associated with 
non-prescription medicines – both of these approaches are grounded in the 
principles of their scientific training. This may suggest that although personal 
judgment was relied upon, they were attempting to rationalise this from a 
scientific stance. 
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Pharmacists were willing to accept new evidence (whether this be efficacy or 
safety data) to inform and change their practice, with more than one 
pharmacist citing recent Medicine and Healthcare Products Regulatory 
Agency advice (UK body regulating supply of medicines). This highlights that 
when robust and reliable information is provided, community pharmacists will 
act upon it and make product recommendations based on evidence. It was 
clear that pharmacists were uncomfortable in recommending products that 
had no evidence of efficacy. This was seen as something that challenged their 
professional ethics and devalued their role as a community pharmacist and 
contravened the principles of their code of conduct [20]. Yet, most 
pharmacists spoke of selling such products. This appeared to be in the 
context of people asking for products by name, and in such circumstances 
pharmacists did state they would explain to the patient the product’s 
effectiveness (or lack of), and again aligns with a professional sense of duty. 
Pharmacists spoke about trying to dissuade people from buying ineffective 
products, yet acknowledging this was often unsuccessful - in these 
circumstances it appeared that pharmacists felt under pressure to supply and 
avoided conflict in the knowledge that the product was going to be safe for the 
person to use. In part, the situation may have arisen because of direct to 
consumer advertising, and has been noted by Chaar et al as disempowering 
pharmacists in non-prescription product selections [21]. Further work is 
needed to explore this consumer/pharmacist relationship in the context of 
optimising care.  
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Pressure also came in the form of commercial targets and the necessity to 
‘make a living’. This commercial-professional conflict has, and will always 
continue to be, an aspect of a profit-driven enterprise such as community 
pharmacy. What came through from this study was that those interviewed 
were cognisant of this fact. A pharmacy could chose not to stock products 
with no evidence of efficacy, but this would potentially put them at a 
commercial disadvantage to others, and without legislation mandating this,  
this seems highly unlikely to happen. 
 
Given EBM is now a cornerstone of medical practice, where do non-
prescription medicines fit with symptom management and the self-care 
agenda? Realistically, without non-prescription medicines and people 
exercising self-care primary healthcare systems would become overloaded 
and unable to cope [22]. It appears that from this study, community 
pharmacists are adopting the principles of EBM where they can but are 
required to adopt a pragmatic approach to product recommendation in the 
absence of evidence. This study did have some limitations. First, the 
participants may not be representative of all community pharmacists 
practicing in England as only one geographic (urban) area of England was 
used to draw the sample and contained only employees or owners. The 
findings centred on commercial pressures may therefore be over-represented 
due to the absence of self-employed pharmacists. Second, the sampling 
strategy used may have introduced bias as those interviewed may have 
stronger opinion toward non-prescription products.  
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Conclusion 
 
Community pharmacists generally used personal judgment based on 
experience and anecdotal evidence to select non-prescription products due to 
the lack of credible evidence associated with them.  
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